Aurobindo Pharma and MSN Laboratories Pvt. Ltd. have opted to deal out of patent infringement litigation brought by AbbVie over the originator’s Fetzima (levomilnacipran hydrochloride) extended-release capsules, with a US district court agreeing to a pair of stipulations and proposed orders of dismissal.
The Indian firms had been pulled up by AbbVie’s Allergan subsidiary and partner Pierre Fabre Medicament over their proposed generic versions